The myelodysplastic syndrome treatment market is projected to grow from USD 3.6 billion in 2025 to USD 6.3 billion by 2035, at a CAGR of 5.9%. Refractory anemia with excess blasts-2 (RAEB-2) will dominate with a 33.6% market share, while chemotherapy will lead the treatment segment with a 41.9% share.